Pharmaceutical industry news

Minnesota Board of Pharmacy fines 4 for drug sales - St. Cloud Times

Minnesota Board of Pharmacy fines 4 for drug sales St. Cloud Times, MN - 25 minutes ago The pharmacy filled prescriptions generated by Internet-based companies ZestRx and ProcessRx and was dispensing analgesics, one of which contained a ...

Global Orthopaedic Developer to Expand Its Indiana Operations

WARSAW, Ind., July 21 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. , a designer, manufacturer and global distributor of orthopaedic devices, announced today it will expand its north central Indiana operations here, creating nearly 100 new jobs by 2011.

The maker of joint replacements, spinal systems and other implants plans to invest more than 9 million to add approximately 50,000 square feet to its foundry operations, boosting automation of the facility and increasing annual output by approximately 1.3 million castings a year.

"Companies like Zimmer can locate new job-creating investment anywhere. For the fourth time in four years, Indiana has won the global competition for new investment from Zimmer, and Hoosiers will benefit from the new jobs the company will create for years to come," said Governor Mitch Daniels.

Headquartered in the Indiana city of 13,000, Zimmer will begin hiring engineers, supervisors and machine operators in 2009 to staff the expanded metal-making facility. The company currently employs approximately 2,800 at its Warsaw operations.

"We are making a number of quality and infrastructure investments to prepare Zimmer to compete in the health care markets of the future," said Zimmer Holdings President and Chief Executive Officer David Dvorak. "The demand for joint replacements continues to grow worldwide and we are pleased to be adding this state-of-the-art foundry to our Warsaw facilities to address growth in a very cost-effective manner."

The Indiana Economic Development Corporation offered Zimmer up to 00,000 in performance-based tax credits based on the company's job creation plans. Warsaw will provide the company with property tax abatement.

"We are very excited that Zimmer is reinvesting in Warsaw," said Warsaw Mayor Ernest B. Wiggins. "The quality of our workforce and their unmatched work ethic continues to be a major factor in growing this vital industry in Indiana."

Zimmer's expansion in Warsaw is the fourth in four years for the 81-year-old company. In 2007, the company announced a 6 million project to add 120,000 square feet to its manufacturing and distribution facility, creating more than 140 new jobs. Two years earlier, the company announced plans to expand its global research and development center, adding 275 high-tech jobs and nearly 100,000 square feet of laboratory workspace to the company's Warsaw West campus. In 2004, the company announced a 4 million project to expand its manufacturing and distribution centers here.

Known as the "Orthopaedic Capital of the World," Warsaw is home to the headquarters of three of the world's five largest makers of artificial joints and related surgical instruments.

About Zimmer

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is a worldwide leader in designing, developing, manufacturing and marketing orthopaedic reconstructive, spinal and trauma devices, dental implants, and related orthopaedic surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.

Zimmer's 2007 sales were approximately .9 billion. The Company is supported by the efforts of more than 8,000 employees worldwide.

About IEDC

Created by Governor Mitch Daniels in 2005 to replace the former Department of Commerce, the Indiana Economic Development Corporation is governed by a 12-member board chaired by Governor Daniels. Indiana Secretary of Commerce Nathan Feltman serves as the chief executive officer of the IEDC. Since Daniels created the IEDC, the state has posted three consecutive years of record-breaking job creation. For more information about IEDC, visit http://www.iedc.in.gov/ .

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. For a list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

Zimmer Holdings, Inc.

CONTACT: Media Contacts: Brad Bishop (Zimmer), 1-574-372-4291 or
Bradley.Bishop@zimmer.com; Mitch Frazier (IEDC), 1-317-232-8873 or
MFrazier@iedc.in.gov; Zimmer Investor Contacts: Paul Blair, 1-574-371-8042 or
Paul.Blair@zimmer.com; James Crines, 1-574-372-4264 or
James.Crines@zimmer.com

Web site: http://www.zimmer.com/
http://www.iedc.in.gov/

MedMira Awarded China Patent to Complete IP Triple Crown - Canada NewsWire (press release)

MedMira Awarded China Patent to Complete IP Triple Crown Canada NewsWire (press release), Canada - 16 hours ago ... our product portfolio for future market growth in personalized healthcare, when over-the-counter (OTC) rapid testing for infectious diseases and other ...

Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2008 Financial Results

ST. DAVID'S, Bermuda, July 21 /PRNewswire-FirstCall/ -- Warner Chilcott Limited announced today that it will issue its second quarter 2008 financial results prior to the market opening on Friday, August 8, 2008.

In addition to issuing a press release, the Company will host a conference call for all interested parties on Friday, August 8, 2008 at 8:00 AM (Eastern Time) to review the results. To participate in the call, please dial (877) 545-1403 in the United States and Canada or (719) 325-4916 internationally.

Investors and other interested parties may also access the conference call via a simultaneous audio webcast by visiting http://ir.wcrx.com/ and clicking on Events & Presentations.

A replay of the conference call will be available for two weeks following the call and can be accessed by dialing (888) 203-1112 within the United States and Canada or (719) 457-0820 internationally. The passcode for the replay is 4102838.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Warner Chilcott Limited

CONTACT: Rochelle Fuhrmann, Investor Relations, 1-973-442-3281,
rfuhrmann@wcrx.com

Web site: http://www.warnerchilcott.com/
http://ir.wcrx.com/

Insmed Provides Update on IPLEX(TM) Programs - CNNMoney.com (press release)

Insmed Provides Update on IPLEX(TM) Programs CNNMoney.com (press release) - 15 hours ago Myotonic muscular dystrophy (MMD), also known as myotonic dystrophy, dystrophia myotonica or Steinerta s disease, is the most common type of adult muscular ...

Drugmaker ills to drive growth, deals in lab sector - guardian.co.uk

Drugmaker ills to drive growth, deals in lab sector guardian.co.uk, UK - Jul 20, 2008 By Deepa Seetharaman NEW YORK, July 20 (Reuters) - A strong five-year run by companies that specialize in pharmaceutical testing shows no sign of slowing as ...

Clinical Trial for the Treatment of Inflammatory Bowel Disease ... - Business Wire (press release)

Clinical Trial for the Treatment of Inflammatory Bowel Disease ... Business Wire (press release), CA - 1 hour ago The clinical trial will explore the efficacy of a formulation developed by Anadis to address the symptoms of Inflammatory Bowel Disease (IBD), ...

High Hopes for New Treatments at Fragile X International Conference

ST. LOUIS, July 21 /PRNewswire/ -- Breakthrough research findings describing potentially significant new treatments for fragile X syndrome (FXS) will be presented to nearly 1,000 family members and professionals at the 11th International Fragile X Conference in St. Louis July 23-27. More than 200 speakers will describe the latest treatments for symptoms related to the mutation of the Fragile X gene and powerful new medications being researched.

Multiple early trials are under way of drugs that show great promise for improving the cognitive, anxiety and behavioral problems associated with FXS.

"Many new treatments target correcting the mechanisms that cause FXS, in contrast to supportive treatments that address various symptoms that dominated past research efforts," wrote Elizabeth Berry-Kravis, M.D., Ph.D., in the National Fragile X Foundation Quarterly (http://www.fragilex.org/html/journals.htm) journal.

Recently featured in Time (http://www.time.com/time/magazine/article/0,9171,1818268,00.html) magazine, Fragile X research is being carried out in all corners of the globe. In the United States, Congress recently appropriated nearly million for continued funding of FXS-related public health activities via the Centers for Disease Control in Atlanta. The National Institutes of Health will fund nearly 5 million in FXS research this year.

The biennial international conference is preceded on July 22 by National Fragile X Awareness Day, proclaimed by Congress in 2000. FXS, the world's leading known cause of inherited intellectual disability (formerly referred to as mental retardation), is also the most common known genetic cause of autism. Scientists are studying FXS as a possible model for better understanding the role that genes play in autism. FXS today affects more than 100,000 Americans. Another one million are carriers of the Fragile X mutation and at risk of passing it on to their children and developing the newly discovered conditions of fragile X-associated tremor/ataxia syndrome (FXTAS), a Parkinson's-like condition causing tremor, balance and memory problems in adults, and fragile X-associated primary ovarian insufficiency (FXPOI), a condition that can result in premature menopause for women as early as their late teens.

For more information, visit the National Fragile X Foundation web site at FragileX.org (http://www.fragilex.org/html/home.shtml).

National Fragile X Foundation

CONTACT: Robert Miller of National Fragile X Foundation,
1-925-938-9300, RobMiller@fragilex.org

Web site: http://www.fragilex.org/
http://www.fragilex.org/html/journals.htm
http://www.time.com/time/magazine/article/0,9171,1818268,00.html
http://www.fragilex.org/html/home.shtml

DJ US Stock Futures Higher; Drug Shares In Focus - Onet.pl

DJ US Stock Futures Higher; Drug Shares In Focus Onet.pl, Poland - 13 hours ago Separately, Sanofi-Aventis said it's paying over 00 million to buy Australia's market leader in vitamins. Time Warner may be active after the new Batman ...

Provectus Pharmaceuticals to Hold Business Update Conference Call ... - Ad-Hoc-News (Pressemitteilung)

Provectus Pharmaceuticals to Hold Business Update Conference Call ... Ad-Hoc-News (Pressemitteilung), Germany - 3 hours ago ... a development-stage oncology and dermatology biopharmaceutical company, will hold a conference call to update the market on its business on Tuesday, ...

Elder Pharma to market Cymbiotics drugs in India - Economic Times

Elder Pharma to market Cymbiotics drugs in India Economic Times, India - 1 hour ago As per the agreement, Elder will market Cymbiotics products in pain management, diabetics, dermatology, besides OTC products. ...

Elder Pharma to market Cymbiotics drugs in India - Economic Times

Elder Pharma to market Cymbiotics drugs in India Economic Times, India - 1 hour ago As per the agreement, Elder will market Cymbiotics products in pain management, diabetics, dermatology, besides OTC products. ...

DGAP-Wp G: Takeover Offer; <DE0005439004> - Finanztreff

DGAP-Wp G: Takeover Offer; <DE0005439004> Finanztreff, Germany - 1 hour ago ... States of America under a sponsored ADR Program (American Depositary Receipt Program) in the OTC market (Over the Counter Market) under ISIN US2107712000.

Astron Clinica Unveils MoleMate(TM), a Revolutionary Skin Cancer Screening System on Vans Warped Tour

NEW YORK, July 21 /PRNewswire/ -- Astron Clinica has partnered with FM World Charities to provide free skin cancer screenings to all attendees on the Vans Warped Tour.

Astron Clinica, a UK-based company with offices in New York and Brisbane, Australia, has recently launched their MoleMate(TM) skin cancer screening system in the US market. MoleMate(TM) is a non-invasive and pain-free melanoma screening device, that will assist Internists, Family Practitioners and skin specialists to scan and evaluate suspicious lesions within seconds and make instant clinical decisions 'on the spot'. Developed by Cambridge, UK-based Astron Clinica, MoleMate(TM), which is clinically proven, includes an easy-to-use decision support system, to provide clear guidelines on how to assess a suspect mole against a database of sample lesions. MoleMate(TM) will make it possible for doctors to identify the best course of action for an unusual mole -- to refer, excise or tell the patient the lesion appears benign -- during the first consultation with a patient. MoleMate(TM) features a magnified dermoscopic view for those medical professionals familiar with dermoscopy and also images of blood, pigment, dermal pigment and collagen up to 2mm beneath the surface of the skin.

The partnership with FM World Charities on the Vans Warped Tour seeks to provide free screenings to the concert attendees and to raise awareness with the youth of America on skin cancer prevention. This is the first time a skin cancer screening initiative has been launched on the Vans Warped Tour.

"MoleMate(TM) has taken the awkwardness out of skin cancer screenings and reduced the need for unneeded biopsies," said Paige Wood, melanoma survivor and artist on the Vans Warped Tour who was instrumental in establishing the revolutionary partnership.

For more information on MoleMate and our initiative on the Vans Warped Tour please contact David Brenner at 516-622-2363 or by email at david.brenner@astronclinica.com. For information about Astron Clinica please visit our website at http://www.astronclinica.com/.

Astron Clinica -- Astron Clinica provides industry leading technology to the medical and aesthetics markets worldwide. Our products include: MoleMate(TM), a skin cancer screening system, Beau Visage(TM), a skin analysis system used by aestheticians and dermatologists for cosmetic procedures, and PhysioMetrics(TM), a system for evaluating body contour changes.

Astron Clinica, LLC

CONTACT: David Brenner of Astron Clinica, LLC, 1-516-622-2363,
david.brenner@astronclinica.com

Web site: http://www.astronclinica.com/

Wyeth Pearl River Facility Earns OSHA VPP Star; 2,000th Workplace Recognized in U.S. Pearl River Becomes 8th Wyeth Site To Achieve OSHA'S Highest Safety Recognition

PEARL RIVER, N.Y., July 21 /PRNewswire-FirstCall/ -- Wyeth announced today that its manufacturing and research facility in Pearl River, N.Y., has earned the highest recognition for workplace safety and health from the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA): the Voluntary Protection Programs (VPP) "star." Wyeth Pearl River is the 2,000th site in the U.S. to be accepted into the VPP, and Wyeth's eighth facility in the country to earn the VPP "star."

"This achievement is the result of a two-and-a-half year effort to make workplace safety the responsibility of every employee on site," said Mike McDermott, Vice President, Site Operations, Wyeth Pearl River. "Safety has always been a top priority in Pearl River, and when we applied for VPP, we set our sights on being the best in the industry. We worked aggressively to make improvements in our safety programs, communication, and training, and we are delighted to be recognized as a VPP 'star' worksite."

OSHA's VPP promotes worksite-based safety and health through collaboration between management, labor and OSHA by establishing cooperative relationships at workplaces that have implemented a comprehensive safety and health management system. Acceptance into VPP is OSHA's official recognition of excellence in occupational safety and health. The "star" designation is the highest of three levels of VPP recognition and is reserved for an elite group of worksites that design exemplary safety and health programs, achieve injury and illness rates at or below the national average of their respective industries, and demonstrate their ability to control workplace hazards. Wyeth earned their VPP "star" in the general industry category.

According to Edwin G. Foulke, Jr., Assistant Secretary of Labor for OSHA, with the induction of Wyeth Pearl River, just 2,000 of the roughly eight million worksites in the country have qualified for the VPP. "This is a significant milestone for Wyeth and for OSHA as Pearl River becomes the 2,000th VPP worksite," said Foulke. "The VPP is a merit-based program that recognizes those exemplary worksites where employees and management work together continuously and effectively to minimize hazards, reduce injuries and illnesses, and enhance safety and health."

In April 2008, a team of OSHA representatives conducted a rigorous, weeklong safety and health assessment at Wyeth Pearl River. Among the areas of excellence identified during OSHA's inspection were integration of safety and health matters into manufacturing process documents, and improvements in self-inspection processes.

Wyeth Among Safest Employers in the Nation

Wyeth Pearl River, which is one of the largest sites in Wyeth's global network, is the company's eighth U.S. facility to earn the VPP "star." The seven other Wyeth sites in the U.S. that have earned "star" recognition are located in:

-- Andover, Mass. -- Research Triangle Park, N.C. -- Sanford, N.C. -- Chazy, N.Y. -- Rouses Point, N.Y. -- two sites -- Richmond, Vir.

Wyeth sites in Cambridge, Mass., Princeton, N.J., and Guayama, Puerto Rico, anticipate undergoing VPP inspections later this year.

"Wyeth is committed to improving the health of people who use our products, and that commitment starts at home with our employees," said McDermott.

Wyeth Pearl River is Rockland County's largest private employer, with approximately 3,200 people. The site manufactures Prevnar(R) infant pneumococcal vaccine, Mylotarg(R), which is used to treat a form of bone marrow cancer, and the Centrum(R) family of multivitamins, the number-one selling multivitamin in the world.

Researchers at Wyeth Pearl River are focused on the discovery and development of novel compounds, innovative therapies and preventative vaccines. Discovery activities are directed to oncology and vaccines therapies, and chemical and screening sciences.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

CONTACT: Grace Ann Arnold of Wyeth Pharmaceuticals, 1-845-602-4768; or
Ted Fitzgerald of U.S. Department of Labor, 1-617-565-2074

Web site: http://www.wyeth.com/

Second asbestos suit filed on pipe-fitter's behalf names 19 defendants - Southeast Texas Record

Second asbestos suit filed on pipe-fitter's behalf names 19 defendants Southeast Texas Record, TX - 24 minutes ago (3M Corporation) and American Optical Corp. for producing defective masks that failed to provide respiratory protection. Although Bergeron has already sued ...

Roche Diagnostics Awards Total Research Grant of 25,040 to Tennessee Pharmacists Research and Education Foundation

NASHVILLE, Tenn., July 21 /PRNewswire/ -- The Tennessee Pharmacists Association (TPA) announced today that the Tennessee Pharmacists Research and Education Foundation has received a total research grant of 25,040 from Roche Diagnostics. The grant fully funds a study to evaluate the effectiveness of the pharmacy-based collaborative approach to diabetes care as compared to current or usual care.

The study is a randomized, controlled pre-test/post-test comprehensive diabetes intervention study conducted by community pharmacists in seven rural or suburban areas across Tennessee. One of the key differences between this study and similar studies is that the recruitment of subjects is physician- driven. The participating pharmacists, working collaboratively with referring physicians and other members of the health care team, will play an active role in the patients' diabetes management and will also be instrumental in the coordination and development of a community referral network to meet specific patient needs.

"We believe that diabetes care delivered in a concerted and organized manner by pharmacists can lead to improvements in outcomes such as A1c, blood pressure, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides and also to a decrease in emergency room visits, hospitalizations and healthcare costs," said Baeteena Black, D.Ph., Executive Director of TPA. "This most generous grant from Roche Diagnostics will allow us to evaluate the difference in outcomes between usual diabetes care and a pharmacy-based collaborative diabetes care program."

Usual care or care received by a control group is defined as the routine diabetes care typically provided in the study site communities by various healthcare professionals. Usual care subjects will be expected to complete baseline, 6-month and 12-month data collection visits. Participants will receive an ACCU-CHEK(R) Aviva meter system and test strips for the length of the study. All subjects will receive training on the use and care of the meters and lancet devices.

Participants in the intervention group will receive individualized care from their site pharmacist, including testing, counseling and education on appropriate medication use, the monitoring of diabetes signs and symptoms, and diabetes patient's self-care behaviors. Each subject in this group will receive a personalized patient care plan, which will be shared with the subject's primary health care provider, who can make any changes to the plan.

"If the effectiveness of this intervention group model is demonstrated through this study, then it may be implemented in other pharmacies throughout Tennessee," said Black.

"This is such an important study for now and the future as healthcare costs associated with diabetes continue to increase rapidly." Black added that costs for the U.S. related to diabetes care, including complications and lost productivity, are about 74 billion a year. "There's good news, though, in that diabetes can be managed successfully with the help of a qualified healthcare team. A small percentage of the 74 billion was spent on testing supplies and medication. The bulk of the expense was related to emergency room visits, hospital stays and operations associated with diabetes complications."

About 1 million new diabetes cases are reported each year, and more than 284,000 Americans lost their battle with diabetes in 2007.

About TPA and TPREF

The Tennessee Pharmacists Association is comprised of pharmacists from every practice setting including community, health-system, long-term care, academia, industry, consulting and more. The mission of TPA is to represent the profession of pharmacy as an integral component of the health care delivery system to entities outside the profession; develop standards of practice which insure delivery of quality pharmaceutical care as a means of protecting and enhancing the public health; promote the enhancement of knowledge, ethics and skills of pharmacists; and insure the economic and professional success of pharmacists in all practice settings.

The Tennessee Pharmacists Research and Education Foundation is a non- profit entity dedicated to advancing the profession of pharmacy through research and education initiatives.

Tennessee Pharmacists Association

CONTACT: Tennessee Pharmacists Association, 1-615-256-3023, Fax:
615/255.3528, tpa@tnpharm.org

Alnylam Grants New InterfeRx(TM) Intellectual Property License to ... - PR-Inside.com (Pressemitteilung)

Alnylam Grants New InterfeRx(TM) Intellectual Property License to ... PR-Inside.com (Pressemitteilung), Austria - 11 minutes ago RNAi therapeutics target the cause of diseases by potently silencing specific messenger RNAs (mRNAs), thereby preventing disease-causing proteins from being ...

South Melbourne Market harbours fine foods - Courier Mail

South Melbourne Market harbours fine foods Courier Mail, Australia - 2 hours ago Doing it the long way, he says, preserves flavour, vitamins and minerals. This is the type of shop where cookbooks are open on the counter and advice is ...

Instrumentation Laboratory and MAS Enter Preferred Vendor Agreement Connecting GEM(R) Premier(TM) 4000 Analyzer with RALS(R)-Plus Connectivity Module

LEXINGTON, Mass. and CHARLOTTESVILLE, Va., July 21 /PRNewswire/ -- Instrumentation Laboratory (IL) and Medical Automation Systems, Inc. (MAS) today announced that they have entered into a Preferred Vendor Agreement (PVA) to interface IL's GEM Premier 4000 analyzers with MAS's RALS-Plus connectivity system. Together, the GEM Premier 4000 and RALS-Plus, offer a complete, streamlined solution for managing testing at the point-of-care and throughout the hospital.

RALS-Plus will enable users of IL's GEM Premier 4000 analyzers to automatically manage, report and electronically transfer patient blood gas data to the RALS-Plus system and the hospital's laboratory information system. The negotiated agreement will also offer preferred customer pricing.

"The RALS-Plus system adds even more simplicity and versatility to the GEM Premier 4000 providing customers an effective and efficient data management solution for testing throughout the hospital," said Ramon Benet, Vice President, WW Marketing and US Sales, of Instrumentation Laboratory. "It's a great example of how IL is continuously seeking ways to help our customers provide optimal patient care."

"As preferred partners, MAS and IL provide integrated solutions that will allow our mutual point-of-care customers to enjoy state-of-the-art connectivity solutions," said Bill Noble, Executive Director of Sales and Marketing of MAS.

About the GEM Premier 4000

The GEM Premier 4000 is a revolutionary blood gas analyzer, with integrated CO-Oximetry, that quickly provides consistent, accurate, lab-quality results throughout the hospital. Self-contained cartridges incorporate all components for patient testing and are maintenance-free. Onboard iQM(R) automates quality control and continuously detects, corrects and documents to assure quality results and compliance, 24/7, regardless of operator or testing location.

About RALS-Plus

RALS-Plus supports several point-of-care device vendors to provide a single solution to manage multiple programs. The connectivity system for point-of-care testing provides users with total control of their point-of-care program. At the click of an icon, you can view results that have been downloaded, display results that have been flagged based on setup criteria, electronically manage system operators, email weekly and monthly reports, and so much more. RALS-Plus is designed to grow a point-of-care program when the managers are ready to grow it. The system's modular design allows for device interfaces to be added meeting demand.

Instrumentation Laboratory (http://www.ilus.com/), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM product offerings, part of the critical care line, include the new GEM Premier 4000 analyzer with Intelligent Quality Management (iQM(R)), GEM Premier 3000 analyzer, GEM OPL(TM), a portable whole blood CO-Oximeter and the GEM PCL Plus, a portable coagulation analyzer. IL's hemostasis portfolio includes the ACL TOP(R) Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP and the new ACL TOP 500 CTS. IL also offers the ACL ELITE(R) and ELITE PRO, other hemostasis analyzers and the HemosIL(R) line of reagents. IL is based in Lexington, Massachusetts.

Medical Automation Systems, Inc. (http://www.medicalautomation.com/) is the country's premier provider of data management systems used by hospitals to monitor and manage diagnostic testing performed at the patient's bedside. Founded in 1994, MAS will have a presence in over 1,600 U.S. hospitals by the end of 2008. With the 1999 Institute of Medicine report on the impact of medical errors on patient mortality and cost of care, an increasing number of hospitals are focused on taking steps to minimize the number of errors tied to patient and specimen identification. RALS-Plus provides a healthcare information technology (IT) solution that can aid in eliminating sources of bedside diagnostic testing identification errors cited in the Institute's report. Other products include RALS-Web, providing instant access to POC results through the hospital intranet; RALS-eQuiz, an on-line training tool with re-certification quizzes and automatic grading; and RALS-TGCM, a Tight Glycemic Control Module featuring graphical reports for those caring for patients on glycemic control protocols. MAS also supports websites that provide source and reference materials on the point-of-care industry and glycemic control protocols. Visit http://www.pointofcare.net/, and http://www.glycemiccontrol.net/.

Instrumentation Laboratory

CONTACT: Sally McCraven of Instrumentation Laboratory, 1-781-861-4577,
smccraven@ilww.com; or Steve Valorz of Medical Automation Systems, Inc.,
1-434-951-2972, ext. 3060, svalorz@rals.com

Web site: http://www.ilus.com/
http://www.medicalautomation.com/
http://www.pointofcare.net/
http://www.glycemiccontrol.net/

Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations

PITTSBURGH, July 21 /PRNewswire-FirstCall/ -- Mylan Inc. announced today the appointment of Daniel E. Crookshank as vice president - Investor Relations and as a member of the company's senior leadership team. Reporting to Chief Financial Officer Edward J. Borkowski, Crookshank is responsible for all investment community communication as well as for the development and direction of activities that proactively promote Mylan to the investment community.

"Dan has a well-deserved reputation as an outstanding, senior investor relations professional," said Mylan Vice Chairman and CEO Robert J. Coury. "His extensive international experience - together with his comprehensive knowledge of finance and solid accounting background - will serve the company well going forward. We're excited to have an individual with Dan's talents joining our Mylan team."

Crookshank served most recently as vice president - Investor Relations for Rockwell Collins, a global manufacturer of communications and aviation electronics solutions for commercial and military customers worldwide. During his 18-year career with Rockwell Collins and Rockwell International, he served in a number of increasingly responsible positions within Finance. Crookshank also completed accounting assignments with National Steel Corporation and H.J. Heinz Corporation. He began his business career with the public accounting firm Deloitte, Haskins & Sells, now Deloitte & Touche.

Crookshank earned a bachelor's degree in business administration from Robert Morris University and an MBA from the Katz Graduate School of Business at the University of Pittsburgh.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

Mylan Inc.

CONTACT: Media, Michael Laffin, or Investors, Kris King, both of Mylan
Inc., 1-724-514-1813

Web site: http://www.mylan.com/

Repros Therapeutics Inc. Announces That the Results of the ... - Business Wire (press release)

Repros Therapeutics Inc. Announces That the Results of the ... Business Wire (press release), CA - 4 hours ago THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that the results of the initial Phase I/II clinical trial of ...

Alembic is banking on exports growth - Sify

Alembic is banking on exports growth Sify, India - 1 hour ago Alembic's acquisition of the non-oncology division of Dabur is aimed at developing more brands. With an established and growing domestic formulation market, ...

Alembic is banking on exports growth - Sify

Alembic is banking on exports growth Sify, India - 1 hour ago Alembic's acquisition of the non-oncology division of Dabur is aimed at developing more brands. With an established and growing domestic formulation market, ...

A new wrinkle for Botox - Pioneer Press

A new wrinkle for Botox Pioneer Press, MN - Jul 19, 2008 In May, the St. Paul-based American Academy of Neurology published guidelines saying that the protein at the heart of Botox hasn't been shown in studies to ...

Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors

ASHBURN, Va., July 21 /PRNewswire/ -- Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors.

Dr. Wild is a co-founder and General Partner of BOWS Pharmaceuticals AG, a Swiss drug-delivery technology company. He is a member of the Boards of Directors of several privately-owned specialty pharmaceutical and biotechnology companies. He also chairs the board of advisors of Ferrer, Freeman and Co., a healthcare private equity firm. He is on the board of advisors of Celtic Therapeutics, a pharmaceutical venture fund and is an advisor to Golden Pond Healthcare Inc., a special acquisitions corporation.

Dr. Wild was the Chairman of MedPointe Pharmaceuticals Inc., a privately-held specialty pharmaceutical company based in Somerset (NJ), until its acquisition by Meda AB of Sweden in 2007. He also served as CEO from 2001 until 2006.

Between 1995 and 2000, Dr Wild worked for the Warner-Lambert Company, of Morris Plains (NJ). Starting as President of Warner-Lambert's Parke-Davis (North America) unit, he was promoted to Executive Vice President and President of its global Pharmaceutical Sector in 1996. Before joining Warner-Lambert, Dr. Wild spent 22 years with the Schering-Plough Corporation in various roles culminating as President of its Japanese operations.

Dr. Wild graduated in 1968 from the University of York where he earned an honors degree in Chemistry. He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).

"We are very fortunate to have Dr. Wild join our board, particularly at this time in Innocoll's aggressive evolution to a world leader in biodegradable surgical products. I have known Tony for a number of years and have found him to be a skillful and successful executive in his prior positions. Innocoll is gaining another professional member to its board to guide the company through this period of ambitious growth," said Rolf Schmidt, Innocoll's Chairman of the board.

"I am excited with the Innocoll products and am impressed with the thorough and well-thought out development plans in place. I look forward to working with the board and management to move the Innocoll portfolio forward to commercialization," said Dr. Wild.

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R), and CRONOCOL(R). In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, an affiliated company of Schering-Plough Corporation and in August 2007 sold its marketing rights, with the exception of the US, to EUSA Pharma. Gentamicin Surgical Implant is currently in phase 3 development in the US for the prevention of surgical site infections. Other late stage pharmaceutical products in Innocoll's development pipeline include CollaRx Gentamicin Topical for the treatment and prevention of infected diabetic foot ulcers and CollaRx Bupivacaine Implant for the management of post-operative pain, both of which are currently in Phase 2 development. For more information, please visit http://www.innocollinc.com/ .

Innocoll Inc.

CONTACT: Veronica Kelly of Innocoll, Inc., 353-9064-86834,
vkelly@innocoll-pharma.com

Web site: http://www.innocollinc.com/

Pathway Wins FDA Approval To Sell Blocked-Artery Buster - Xconomy

Pathway Wins FDA Approval To Sell Blocked-Artery Buster Xconomy, MA - 1 hour ago The company stumbled six years later when it couldna t win new investment for treating cardiovascular disease. Then an investor syndicate convinced Clement ...

NZ's first private cancer centre - TVNZ

NZ's first private cancer centre TVNZ, New Zealand - 21 minutes ago But Southern Cross Insurance, with two thirds of the market, has yet to decide. Andrew Wong of Auckland Radiation Oncology says going ahead with the new ...

Roche 1st Half Net Profit CHF5.73 Billion Vs CHF5.86 Billion - Smartmoney.com

Roche 1st Half Net Profit CHF5.73 Billion Vs CHF5.86 Billion Smartmoney.com - 2 hours ago ... first market worldwide for this indication. - Acquisition of Piramed (UK) strengthens R&D pipeline in oncology and inflammatory disease. ...

Web Pick of the Week - Publishers Weekly

Web Pick of the Week Publishers Weekly, NY - 12 minutes ago ... the two-decade increase in reported cases (ita s now a the fastest-growing infectious disease in Americaa ), symptoms (which can be a arthritic, ...